<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051336</url>
  </required_header>
  <id_info>
    <org_study_id>TAR-100-101</org_study_id>
    <nct_id>NCT01051336</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of the Taris Placebo System</brief_title>
  <official_title>Phase I Safety and Tolerability Study of the Taris Placebo System (A Novel Bladder Drug Delivery Platform)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TARIS Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TARIS Biomedical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this protocol is to evaluate the tolerability of the Taris placebo system for the
      development program and to provide key safety and tolerability data for the Taris platform.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, tolerability and retention of the TARIS placebo system upon insertion, 14-day exposure and removal</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject reported symptoms</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Routine and microscopic urinalysis</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine culture</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TARIS Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Procedure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TARIS Placebo</intervention_name>
    <arm_group_label>TARIS Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Procedure</intervention_name>
    <arm_group_label>Sham Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female volunteers, 18 to 55 years of age

          -  Body weight &gt;100 lbs and BMI (body mass index) within the range 18-30 kg/m2

          -  A score of less than 11 on the pelvic pain/urgency-frequency scale (PUF)

        Exclusion Criteria:

          -  Presence of any bladder or urethra anatomical feature that, in the opinion of the
             investigator, might prevent the safe placement, indwelling use, or removal of the
             TARIS placebo system

          -  History of significant urogenital surgery (any type of bladder suspension, prolapse
             repair, incontinence procedure, or vaginal hysterectomy)

          -  History of kidney stone formation

          -  Chronic or recurring bacterial or viral infections of the urogenital system
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pankaj M Jain, M.D., M.B.A.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dedicated Phase I (Arizona Urology)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <last_update_submitted>January 15, 2010</last_update_submitted>
  <last_update_submitted_qc>January 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Julie Himes, M.D. / Chief Medical Officer</name_title>
    <organization>TARIS Biomedical</organization>
  </responsible_party>
  <keyword>TARIS Placebo</keyword>
  <keyword>Bladder</keyword>
  <keyword>Interstitial Cystitis</keyword>
  <keyword>Normal Healthy Volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

